GEHCNasdaq

GE HealthCare Technologies Inc.

Healthcare·Oncology·Commercial·Chicago, IL, United States
OncologyNeurologyCardiovascular

GE HealthCare Technologies Inc. (GEHC): 14 pipeline candidates · 1 upcoming catalyst · ~10 mo cash runway · 5 clinical trials. Updated within the last hour.

6.2/10

BioSniper Score

6-factor signal · derived from public data

Cash Runway2.7

9.7 months

Financial Health2.6

D/E 2.46

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth10.0

14 candidates

Catalyst Momentum2.0

1 upcoming, next in ~821d

Insider Signal10.0

8 buys · 0 sells (180d)

A transparent, data-derived signal for GE HealthCare Technologies Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$29.6B

Cash

$2.3B

Quarterly Burn

$1.5B

Runway

9.7 mo

Revenue

$5.1B

Cash Runway vs Catalysts

A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.

Cash ends ~Apr 2027
Today~30 mo out
Catalyst within runwayCatalyst after cash runs out

Pipeline (14 candidates)

Showing 10 of 14 candidates. Sign up for full pipeline.

Upcoming Catalysts (1)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

1,258

Total value held

$28.04B

HolderSharesValue
vanguard capital management llc57,728,376$4.11B
blackrock, inc.35,984,327$2.56B
dodge & cox31,312,064$2.23B
state street corp20,538,476$1.46B
vanguard portfolio management llc19,183,157$1.37B
harris associates l p15,594,988$1.11B
geode capital management, llc12,399,635$879.3M
barrow hanley mewhinney & strauss llc11,884,588$845.9M
hotchkis & wiley capital management llc9,967,873$709.5M
jpmorgan chase & co8,964,669$616.5M

Showing top 10 of 1,258 institutional holders of GE HealthCare Technologies Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

5 clinical trials·9 FDA decisions·CEO: Mr. Peter J. Arduini

Frequently asked questions

How many drug candidates are in GE HealthCare Technologies Inc.'s pipeline?

GE HealthCare Technologies Inc. (GEHC) has 14 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is GE HealthCare Technologies Inc.'s lead drug candidate?

GE HealthCare Technologies Inc.'s most advanced tracked candidate is achilles insight ultrasonometer (Approved) for Radiology.

What is GE HealthCare Technologies Inc.'s next catalyst?

GE HealthCare Technologies Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: VIZAMYL" — expected September 16, 2028.

What is GE HealthCare Technologies Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, GE HealthCare Technologies Inc. has approximately 9.7 months of cash runway.

What is GE HealthCare Technologies Inc.'s market capitalization?

GE HealthCare Technologies Inc.'s market capitalization is approximately $29.6B.

Get the full picture on GE HealthCare Technologies Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.